Cheng Kenneth T.
National Center for Biotechnology Information, NIH, NLM, Bethesda, MD,
[F]1-(2-Fluoroethyl)-4-[4-cyanophenoxy)methyl]piperidine ([F]SFE) is a radioligand developed for positron emission tomography (PET) imaging of the sigma (σ) receptors (1-3). F]SFE is a potent σ receptor agonist labeled with F, a positron emitter with a physical half-life () of 109.8 min. σ receptors are functional, membrane-bound, G-protein-coupled receptors distributed in the central nervous system (CNS) and peripheral organs (4). The CNS σ receptors are unique binding sites related to higher brain functions (5). They are distinct from opiate and phencyclidine binding sites. There are at least two subtypes of sigma receptors, σ and σ receptors. The precise mechanism of the functional response of these receptors is not entirely known. These receptors appear to be involved in numerous pharmacological and physiological functions, and they also modulate a number of central neurotransmitter systems, including noradrenergic, glutamatergic, and dopaminergic systems. Phencyclidine and derivatives, cocaine and derivatives, some neuroleptics, atypical antipsychotic agents, and other chemically unrelated compounds can bind to the σ receptor sites. Studies have shown that these receptors may play a role in the pathogenesis of psychiatric disorders (6, 7). These receptors are also expressed on a number of human and murine tumors (8). The σ receptor subtypes have a molecular weight of ≈25 kDa, and through the process of cloning they have shown a 30% sequence homology with the yeast C89-C7 sterol isomerase (4, 9, 10). The σ receptor subtypes have a molecular weight of ≈21.5 kDa, and have not been cloned. The σ receptors are thought to be involved in certain neuropsychiatric disorders, and the σ receptors are also implicated in malignant neoplastic diseases. Because of these effects, σ receptor ligands may be useful for detection and treatment in neurology and oncology. A number of ligands for these receptors have been labeled with C and F for PET imaging to map their brain distribution and expression on tumors (11). Waterhouse et al. (12, 13) synthesized a number of selective σ receptor ligands for both PET and single-photon emission computed tomography. [F]1-(3-Fluoropropyl)-4-(4-cyanophenoxy-methyl)piperidine ([F]FPS) was found to be a high-affinity σ receptor ligand with a dissociation constant () of 0.5 nM, but it was not cleared fast enough from the CNS to reach transient equilibrium by 4 h after administration in healthy volunteers (3). In an effort to improve the CNS clearance for PET studies, Zhao et al. (3) synthesized and evaluated [F]SFE ( = 5 nM), a analog of [F]FPS analog that exhibits a lower affinity for σ receptor ligands.
[F]1-(2-氟乙基)-4-[4-氰基苯氧基)甲基]哌啶([F]SFE)是一种开发用于西格玛(σ)受体正电子发射断层扫描(PET)成像的放射性配体(1 - 3)。[F]SFE是一种用氟标记的强效σ受体激动剂,氟是一种物理半衰期(t1/2)为109.8分钟的正电子发射体。σ受体是功能性的、膜结合的、G蛋白偶联受体,分布于中枢神经系统(CNS)和外周器官(4)。中枢神经系统σ受体是与高级脑功能相关的独特结合位点(5)。它们与阿片类和苯环己哌啶结合位点不同。西格玛受体至少有两种亚型,即σ1和σ2受体。这些受体功能反应的确切机制尚不完全清楚。这些受体似乎参与了许多药理和生理功能,并且它们还调节一些中枢神经递质系统,包括去甲肾上腺素能、谷氨酸能和多巴胺能系统。苯环己哌啶及其衍生物、可卡因及其衍生物、一些抗精神病药物、非典型抗精神病药物以及其他化学上无关的化合物可以与σ受体位点结合。研究表明,这些受体可能在精神疾病的发病机制中起作用(6,7)。这些受体也在许多人类和小鼠肿瘤中表达(8)。σ1受体亚型的分子量约为25 kDa,通过克隆过程显示与酵母C89 - C7甾醇异构酶有30%的序列同源性(4,9,10)。σ2受体亚型的分子量约为21.5 kDa,尚未克隆。σ1受体被认为与某些神经精神疾病有关,σ2受体也与恶性肿瘤疾病有关。由于这些作用,σ受体配体可能对神经病学和肿瘤学的检测和治疗有用。许多针对这些受体的配体已用碳-11和氟-18标记用于PET成像,以绘制它们在脑中的分布以及在肿瘤上的表达(11)。沃特豪斯等人(12,13)合成了许多用于PET和单光子发射计算机断层扫描的选择性σ受体配体。[F]1-(3-氟丙基)-4-(4-氰基苯氧基甲基)哌啶([F]FPS)被发现是一种高亲和力的σ受体配体,其解离常数(Kd)为0.5 nM,但在健康志愿者给药后4小时内,它从CNS清除得不够快,无法达到瞬时平衡(3)。为了改善PET研究中的CNS清除率,赵等人(3)合成并评估了[F]SFE (Kd = 5 nM),它是[F]FPS的类似物,对σ受体配体表现出较低的亲和力。